Criteria Fulfill
Item
each patient had to meet the following criteria to be eligible for the study:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
de novo myelodysplastic syndromes | secondary myelodysplastic syndromes | Age | Disease French-American-British Classification | Leukemia, Myelomonocytic, Chronic | White Blood Cell Count | International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes | Complete Blood Count | Bone Marrow Assessment | Bone Marrow Cytogenetic Analysis
Item
1. patients with mds (de novo or secondary) must have been 60 years or older and have had disease fitting any of the recognized french-american-british classifications or chronic myelomonocytic leukemia (with white blood cell [wbc] <12,000/μl) and have had an international prognostic scoring system score of ≥1.5 as determined by complete blood count, bone marrow assessment and bone marrow cytogenetics within 30 days of study entry.
boolean
C0280451 (UMLS CUI [1])
C0280745 (UMLS CUI [2])
C0001779 (UMLS CUI [3])
C0012634 (UMLS CUI [4,1])
C2984084 (UMLS CUI [4,2])
C0023480 (UMLS CUI [5])
C0023508 (UMLS CUI [6])
C2827405 (UMLS CUI [7])
C0009555 (UMLS CUI [8])
C0005953 (UMLS CUI [9,1])
C1516048 (UMLS CUI [9,2])
C0005953 (UMLS CUI [10,1])
C0752095 (UMLS CUI [10,2])
Leukemia, Myelocytic, Acute | Bone marrow Blasts Percentage | Age | Induction Chemotherapy Standard | Standard therapy failed
Item
2. patients with aml (≥30% bone marrow blasts) must have been age 18 years or older and had previously received standard induction chemotherapy and/or had failed approved therapies.
boolean
C0023467 (UMLS CUI [1])
C1982687 (UMLS CUI [2,1])
C0439165 (UMLS CUI [2,2])
C0001779 (UMLS CUI [3])
C3179010 (UMLS CUI [4,1])
C1442989 (UMLS CUI [4,2])
C2936643 (UMLS CUI [5,1])
C0231175 (UMLS CUI [5,2])
ECOG performance status
Item
3. must have had eastern cooperative oncology group (ecog) performance status of 0 to 2.
boolean
C1520224 (UMLS CUI [1])
Informed Consent
Item
4. must have signed an institutional review board (irb)-approved informed consent form, indicating his/her awareness of the investigational nature of this study and its potential hazards prior to initiation of any study-specific procedures or treatment.
boolean
C0021430 (UMLS CUI [1])
Renal function | Liver function | Creatinine measurement, serum | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
5. must have had adequate renal and hepatic function (creatinine ≤2.0 mg/dl, total bilirubin <2.0 mg/dl, aspartate aminotransferase (ast) and alanine aminotransferase (alt) <3.0 x institutional upper limit of normal).
boolean
C0232804 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0201976 (UMLS CUI [3])
C1278039 (UMLS CUI [4])
C0201899 (UMLS CUI [5])
C0201836 (UMLS CUI [6])
Life Expectancy
Item
6. must have had life expectancy of at least 12 weeks.
boolean
C0023671 (UMLS CUI [1])
Therapeutic procedure Toxic effect Patient recovered
Item
7. must have recovered from all toxic effects of all prior therapy before entry into this study.
boolean
C0087111 (UMLS CUI [1,1])
C0600688 (UMLS CUI [1,2])
C1115804 (UMLS CUI [1,3])
MYELODYSPLASTIC SYNDROME | High-dose chemotherapy | Bone Marrow Transplantation | Stem cell transplant
Item
1. patients with mds must not have been candidates for high-dose chemotherapy, bone marrow or stem cell transplant.
boolean
C3463824 (UMLS CUI [1])
C1328050 (UMLS CUI [2])
C0005961 (UMLS CUI [3])
C1504389 (UMLS CUI [4])
Acute Promyelocytic Leukemia French-American-British Classification
Item
2. must not have had acute promyelocytic leukemia (m3 classification).
boolean
C0023487 (UMLS CUI [1,1])
C2984084 (UMLS CUI [1,2])
Therapeutic immunosuppression
Item
3. must not have received immunosuppressive therapy for 30 days prior to study entry.
boolean
C0021079 (UMLS CUI [1])
Central nervous system leukaemia
Item
4. must not have had central nervous system (cns) leukemia.
boolean
C1332884 (UMLS CUI [1])
CORTICOSTEROIDS FOR SYSTEMIC USE | Interferon | Interleukins | Hormone Therapy | Topical corticosteroids | inhaled steroids | Steroids Prophylactic treatment Transfusion Reaction
Item
5. must not have received systemic corticosteroids, interferon, interleukins or other hormonal therapy within 30 days prior to study entry. use of corticosteroids (topical and inhaled corticosteroids) was permitted and prophylactic steroids may have been used to treat or prevent transfusion reactions.
boolean
C3653708 (UMLS CUI [1])
C3652465 (UMLS CUI [2])
C0021764 (UMLS CUI [3])
C0279025 (UMLS CUI [4])
C0304604 (UMLS CUI [5])
C2065041 (UMLS CUI [6])
C0038317 (UMLS CUI [7,1])
C0199176 (UMLS CUI [7,2])
C0274435 (UMLS CUI [7,3])